Search Results
Your search for what matches 6155 pages
Showing 1601 - 1650Expert Point of View: Lucia Masarova, MD
Lucia Masarova, MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, said the updated long-term data for momelotinib show “durable efficacy and exciting outcomes” in patients with myelofibrosis, regardless of prior exposure to...
I Let Science, Not Emotion, Dictate My Treatment
I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...
Ongoing Surveillance and Efforts to Reduce Smoking and Obesity Needed to Lower Cancer Survivors’ Risks of New Cancers
The risk of developing or dying of a new primary cancer, particularly those cancers associated with smoking and obesity, was greater among survivors of adult-onset cancers than the expected risk in the general population, according to an analysis of data from more than 1.5 million cancer...
John Bartlett, MD, Pioneer in Infectious Diseases Research and Treatment, Dies at 83
John Bartlett, MD, a visionary physician-scientist and pioneer in HIV/AIDS study and treatment who built the infectious diseases division at The Johns Hopkins, died on January 19, 2021, in New York. He was 83 years old. “Over his long and illustrious career, John Bartlett epitomized the best of...
Joseph V. Simone, MD, Visionary Pediatric Oncologist and ‘Quintessential Mentor,’ Dies at 85
When Joseph V. Simone, MD, was 6 years old, he had his first experience with the death of a child. His 9-month-old brother became sick with the croup and was taken to the nearby children’s hospital, where he died a few days later, leaving Dr. Simone and his family devastated. Caring for sick...
Oncology Community Mourns the Death of Chemotherapy Pioneer Emil J Freireich, MD, FASCO
Legendary oncologist Emil J Freireich, MD, FASCO, died from COVID-19 on February 1, 2021, at The University of Texas MD Anderson Cancer Center in Houston, where he had worked for 50 years. He was 93. During a career that spanned more than 6 decades, Dr. Freireich was relentless in pursuing cures...
COVID-19 and Cancer: A Toxic Combination
COVID-19 has caused 475,000 deaths in America, disproportionately among communities of color, poverty, immigrants, and older age. It has exposed a variety of inequities within our health-care system. However, the patients at greatest risk of death from COVID-19 are those with cancer. While 1.8% of...
How the COVID-19 Pandemic Can Help Improve Cancer Research
The ripple effects of the coronavirus pandemic have been felt in every area of health care. In our medical specialty, oncology, clinical trials of new treatments were upended by COVID-19. In the early months of the pandemic, widespread interruptions in trial enrollment prevented some patients...
One-Third of Cancer Survivors Reported Worry About Health-Care Disruptions Early in the COVID-19 Pandemic
A new study published by Corinne Leach, MPH, MS, PhD, and colleagues in the Journal of Psychosocial Oncology reported that early in the COVID-19 pandemic in the United States, one-third of cancer survivors worried about treatment and cancer care disruptions. Using a mixed-methods approach,...
Expert Point of View: Meredith Regan, ScD, and Sara Hurvitz, MD
In the San Antonio meeting’s closing session, “View From the Trenches: What Will You Do Monday Morning?” Meredith Regan, ScD, and Sara Hurvitz, MD, offered their thoughts on the use of RSClin in the clinic, as described at the San Antonio Breast Cancer Symposium by Joseph Sparano, MD.1 Dr. Regan...
Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL
Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s tyrosine kinase (BTK) inhibitors and BCL2...
Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies
Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to a study presented at the 2020...
ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
KEYNOTE-427: First-Line Pembrolizumab in Advanced Clear Cell Renal Cell Carcinoma
As reported in the Journal of Clinical Oncology by McDermott et al, findings in a cohort of the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment for advanced clear cell renal cell carcinoma. In a separate cohort of the study,...
Have Breast Cancer Mortality Rates Stopped Declining for Younger Women?
Breast cancer death rates have stopped declining for women in the United States younger than age 40, ending a trend that existed from 1987 to 2010, according to a report published by Hendrick et al in Radiology. Breast cancer is the most common nonskin cancer and the second most common cause of...
Study Links Exposure to Nighttime Artificial Lights With Possible Elevated Risk of Thyroid Cancer
People living in regions with high levels of outdoor artificial light at night may face a higher risk of developing thyroid cancer, according to a study published by Zhang et al in the journal Cancer. Link Between Nighttime Light and Cancer Risk Over the past century, nightscapes—especially in...
Expert Point of View: Lucia Masarova, MD
Lucia Masarova, MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, said the updated long-term data for momelotinib show “durable efficacy and exciting outcomes” in patients with myelofibrosis, regardless of prior exposure to...
Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also...
Expert Point of View: William Gradishar, MD
William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center, commented on the findings of the ASCENT biomarker analysis in the closing panel discussion. The...
Phase II PRIMO Dose-Optimization Trial of Duvelisib in Peripheral T-Cell Lymphoma
Researchers at the ASH Annual Meeting and Exposition reported high response rates in patients with relapsed peripheral T-cell lymphoma after treatment with single-agent duvelisib, a dual PI3K inhibitor.1 Barbara Pro, MD, of Robert H. Lurie Comprehensive Cancer Center, Northwestern University...
ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
Understanding Patients’ Needs and Preferences: Cancer Care Stakeholders Explore Barriers and Best Practices
The keynote speaker did not mince words. “I tell everyone, do not use the term age-appropriate therapy,” said Jan White, a cancer survivor and patient advocate who described her own experience with stage IV non-Hodgkin lymphoma. “Patients with cancer,” she said, “are more than their age, gender,...
Expert Point of View: Jacob Soumerai, MD
Jacob Soumerai, MD, Assistant Professor at Harvard Medical School and Massachusetts General Hospital Cancer Center, who was not involved in this study, commented on the MURANO study findings. “MURANO is the definitive phase III trial that established venetoclax/rituximab as a standard of care for...
Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79
Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature. “At St. Jude, the nature of our work requires a bold, ambitious...
FDA Update: Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate, Statement on Product Development to Address Virus Variants
On February 4, the U.S. Food and Drug Administration (FDA) announced the scheduling of a meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the request for emergency use authorization for a COVID-19 vaccine from Janssen Biotech Inc. Additionally, Acting...
WCLC Press Briefing Focuses on the Connection Between Lung Cancer and COVID-19
On February 27, 2020, the Journal of Thoracic Oncology published a case study that described two patients from Wuhan, China, who had recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. Eleven months later, the lung...
Expert Point of View: Virginia Kaklamani, MD
Press conference moderator Virginia Kaklamani, MD, of UT Health San Antonio, and Leader of the Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center, weighed in on this study. “This study compared patients’ reports with physicians’ reports about the severity of symptoms. It is a...
New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on screening in survivors’ later years. The guidelines, published today by Rachel A. Freedman, MD, MPH, and ...
Early Research Explores Relationship Between CD58 Loss and Resistance to CAR T-Cell Therapies
Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to an experimental study presented...
Study Identifies Four Unique Subtypes of Small Cell Lung Cancer
Researchers have developed the first comprehensive framework to classify small cell lung cancer (SCLC) into four unique subtypes based on gene expression and have identified potential therapeutic targets for each type. These findings were published by Gay et al in Cancer Cell. SCLC is known for...
It All Began With a Lump in the Throat
BOOKMARK Title: Milkshakes and Morphine: A Memoir of Love and LifeAuthor: Genevieve FoxPublisher: VintagePublication date: January 2019Price: $15.95, paperback, 384 pages “It doesn’t hurt, but I know it is there and I know it shouldn’t be. Interloper. I have touched it a couple of times already,...
New NCCN Resource Offers Practical Suggestions for Cancer Survivors
The National Comprehensive Cancer Network (NCCN) has announced the publication of new, free informational resources on health and wellness for cancer survivors. These two new NCCN Guidelines for Patients® are focused on healthy living and managing late and long-term side effects, and they include...
Mayo Clinic Care Network Expands to Include Minnesota Oncology
The first independent, community oncology practice recently joined the Mayo Clinic Care Network. Minnesota Oncology comprises a group of carefully vetted, independent health-care providers with special access to the Mayo Clinic’s knowledge and expertise, including its research, diagnostic, and...
Kenneth H. Kim, MD, to Lead Cedars-Sinai Women’s Cancer Program
Cedars-Sinai Cancer Center has announced that Kenneth H. Kim, MD, will direct its Division of Gynecologic Oncology. Dr. Kim also serves as Chair of the institution’s Committee for Oversight of Training and Education. The appointment reflects Dr. Kim’s breadth of experience, which involves novel...
Expert Point of View: C. Kent Osborne, MD, and Ruth M. O’Regan, MD
Commentary for monarchE and PENELOPE-B was provided by C. Kent Osborne, MD, and Ruth M. O’Regan, MD, respectively. Dr. Osborne is Professor of Medicine, Hematology, and Oncology and the Dudley and Tina Sharp Chair for Cancer Research at Baylor College of Medicine, as well as Founding Director of...
Indian Surgical Oncologist Offers Insights Into Delivering Equitable Cancer Care in a Resource-Challenged Country
The ASCO Post is pleased to introduce this department on Global Health-Care Equity. On an occasional basis, we will publish interviews between Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, and another oncologist or cancer care specialist spanning regions around the world. Our goal is to...
Expert Point of View: Sagar Lonial, MD, and Adam D. Cohen, MD
The studies of ALLO-715 “off-the-shelf” CAR T-cell therapy and bb21217 impressed two experts in the field. Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, and Adam D. Cohen, MD, ...
Expert Point of View: Yuan Yuan, MD, PhD
Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, said that this was yet another failed phase III trial following promising phase II data. “Entinostat was granted Fast Track designation by the U.S. Food and Drug Administration several years back based on preclinical and...
ASCO’s New Chief Medical Officer Plans to Tackle the Global Burden of Cancer and Disparities in Access to Care
In November, ASCO announced that Julie R. Gralow, MD, FACP, FASCO, will succeed Richard L. Schilsky, MD, FACP, FSCT, FASCO, as Chief Medical Officer (CMO) of the Society. Dr. Gralow will begin her new position on February 15, 2021. Dr. Gralow’s long relationship with ASCO dates back to 1995, when...
Gastrointestinal Oncologist Laura Goff, MD, Sees Potential in Emerging Immunotherapies and Novel Targeted Agents
Laura Goff, MD, Medical Director of the Hematology and Oncology Division at Vanderbilt-Ingram Cancer Center, Nashville, was born in Chicago but reared in Lewisville, a suburb of Dallas. “I come from a long line of nurses, which early on influenced my decision to pursue a career in medicine....
Chronic Graft-vs-Host Disease: Future Directions in Treatment
Hematopoietic stem cell transplantation (HSCT) has improved survival rates for several hematologic malignancies, but as the number of transplants continues to rise, community oncologists are evaluating more posttransplant complications in the clinics. The ASCO Post spoke with two of the principals...
Community Oncology Alliance Elects New President, Officers, and Board Members
The Community Oncology Alliance (COA), a nonprofit advocacy group dedicated solely to independent oncology practices and the patients they serve, recently announced the election of Kashyap Patel, MD, as President. A longtime COA Board of Directors member and community oncology champion, Dr. Patel...
COVID-19 and Integrative Oncology: Meeting the Global Challenges of Health Equity
Guest Editor’s Note: Due to COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2020 international conference in a virtual format. It focused on key issues of health disparities in integrative cancer care, innovative integrative oncology service delivery models, and...
Expert Point of View: Alphonse G. Taghian, MD
Alphonse G. Taghian, MD, Professor at Harvard Medical School and Co-Director of Breast Cancer Research Program at Massachusetts General Hospital, Boston, said that these results from the PRIME II trial are quite similar to those of the older CALGB study first initiated in 1994.1 Both studies had a ...
New Study Investigates Role of Ultraviolet Radiation in Conjunctival Melanoma
Ultraviolet (UV) radiation may contribute to the development of a rare type of eye cancer, conjunctival melanoma, according to research published by Mundra et al in Nature Communications. The new study has revealed similar genetic changes in patients with conjunctival melanoma to those with...
Distinct T-Cell Signature in Black Patients With Breast Cancer May Contribute to More Aggressive Disease
A research team has revealed a distinct molecular signature in the tumor tissues of Black patients with breast cancer. The new work, published by Yao et al in JNCI: Journal of the National Cancer Institute, reported that an elevated number of “exhausted,” nonfunctional T cells appears to lead to...
Facebook Posts and the Spread of Incorrect Information About Perceived Risks of HPV Vaccination
The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, according to the Centers for Disease Control and Prevention (CDC). HPV is associated with health problems—including cancers—but a vaccine for the virus has been available since 2006. The CDC...
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
On January 4, U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, MD, PhD, issued the following statement on FDA-authorized dosing schedules for each COVID-19 vaccine. Two different mRNA...
